Hematogenous Osteomyelitis Relapse, Osteomyelitis
Conditions
Keywords
Hematogenous osteomyelitis, relapse, adulthood
Brief summary
To our knowledge, few cases of relapse in adulthood are described in the literature except in patients with sickle cell disease and the epidemiological, clinical, laboratory, radiological features and the management of osteomyelitis relapsing in adulthood are not described. The aim of this retrospective multicentric cohort study : in France is to describe the epidemiological, clinical, laboratory, and radiological features and the management of adult patients who experienced a relapse between 2003-2015 of an acute hematogenous osteomyelitis acquired in the childhood (description of characterization of the period between the first episode of osteomyelitis and the second episode, description of signs of relapse and description of treatments used in the relapse). The data are analysed with non-comparative descriptive statistics.
Interventions
None listed
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients (≥ 18 years) who presented a relapse between 2003-2015 of a hematogenous osteomyelitis acquired in childhood. * the time limit between the 2 episodes must be at least 2 years * antecedent of osteomyelitis before 16 years
Exclusion criteria
* inability to give the information to the patient * patients opposed to the use of their data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of patients having an osteomyelitis | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | Description of the population |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| rate of bacteria responsible for infection | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | bacterial epidemiology |
| rate of management with surgery | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | Description of type of surgery |
| Rate of Treatment Failure | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin |
Countries
France
Outcome results
None listed